Mendes Diogo, Alves Carlos, Loureiro Márcia, Fonte Ana, Batel-Marques Francisco
AIBILI - Association for Innovation and Biomedical Research on Light and Image, CHAD - Centre for Health Technology Assessment and Drug Research, UFC - Pharmacovigilance Unit of Coimbra, Coimbra, Portugal.
School of Pharmacy, Laboratory of Social Pharmacy and Public Health, University of Coimbra, Coimbra, Portugal.
J Clin Pharm Ther. 2019 Feb;44(1):54-61. doi: 10.1111/jcpt.12752. Epub 2018 Aug 1.
Hypersensitivity adverse drug reactions (HADRs) are associated with considerable morbidity and mortality. The aim of this study was to identify cases of HADRs within a hospital electronic health records (EHR) database.
Data were extracted from EHR through the Portuguese catalogue of allergies and other adverse reactions (CPARA). This registry allows the collection and sharing of information on HADRs in a structured and harmonized way across the healthcare system. This module is used by healthcare professionals to record HADRs within the EHR of each patient. It applies to patients admitted to hospital because of HADRs and also to inpatients developing such reactions during hospitalization. Data recorded from 2013 to 2017 within the Centro Hospitalar de Entre o Douro e Vouga (CHEDV) hospital (397 beds; ≈20 300 inpatients/year) were considered. The MedDRA classification was used to codify HADRs. The ATC classification system was used to codify drugs. The concept of individual case safety report (ICSR) was considered for performing analyses.
The database contained 464 valid cases (severe, n = 330; 71.1%), corresponding to 380 patients and 559 HADRs. Most patients were female (n = 254; 66.8%); the median age was 55 years. Approximately 0.1% local inhabitants and ≈0.4% inpatients have experienced HADRs over the study period. Most cases (n = 245; 52.8%) were associated with systemic antibacterials. Most HADRs were skin and subcutaneous tissue disorders (n = 266; 47.6%) and immune system disorders (n = 231; 41.3%). The pattern of suspected drugs implicated in anaphylactic reactions was the same as those involved in other HADRs.
This registry contains HADRs that are relevant for the pharmacovigilance system, but none was spontaneously reported. The responsible authorities should address this problem. The results also reinforce the association between systemic antibacterials and HADRs.
超敏性药物不良反应(HADRs)与相当高的发病率和死亡率相关。本研究的目的是在医院电子健康记录(EHR)数据库中识别HADRs病例。
通过葡萄牙过敏及其他不良反应目录(CPARA)从EHR中提取数据。该登记系统允许在整个医疗系统中以结构化和统一的方式收集和共享HADRs信息。医疗专业人员使用此模块在每个患者的EHR中记录HADRs。它适用于因HADRs入院的患者以及住院期间发生此类反应的住院患者。考虑了2013年至2017年期间在杜罗河与沃加河中央医院(CHEDV)(397张床位;每年约20300名住院患者)记录的数据。使用MedDRA分类法对HADRs进行编码。使用ATC分类系统对药物进行编码。在进行分析时考虑了个体病例安全报告(ICSR)的概念。
该数据库包含464例有效病例(严重病例,n = 330;71.1%),对应380名患者和559例HADRs。大多数患者为女性(n = 254;66.8%);中位年龄为55岁。在研究期间,约0.1%的当地居民和约0.4%的住院患者经历过HADRs。大多数病例(n = 245;52.8%)与全身性抗菌药物有关。大多数HADRs为皮肤和皮下组织疾病(n = 266;47.6%)和免疫系统疾病(n = 231;41.3%)。过敏反应中涉及的可疑药物模式与其他HADRs中涉及的相同。
该登记系统包含对药物警戒系统有意义的HADRs,但无一例是自发报告的。相关当局应解决这一问题。结果还强化了全身性抗菌药物与HADRs之间的关联。